In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on ESSA Pharma (EPIX – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $6.20.
Gershell covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Crinetics Pharmaceuticals, and Cytokinetics. According to TipRanks, Gershell has an average return of 1.9% and a 35.91% success rate on recommended stocks.
ESSA Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $17.50, a 182.26% upside from current levels. In a report released on May 14, JonesTrading also maintained a Buy rating on the stock with a $18.00 price target.
The company has a one-year high of $11.67 and a one-year low of $2.58. Currently, ESSA Pharma has an average volume of 68.57K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPIX in relation to earlier this year. Last month, Richard M Glickman, a Director at EPIX bought 3,750.00 shares for a total of $18,375.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ESSA Pharma (EPIX) Company Description:
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
